Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 23.94 -2.13% -0.52
DCPH closed down 2.13 percent on Friday, March 22, 2019, on 1.27 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DCPH trend table...

Date Alert Name Type % Chg
Mar 22 Stochastic Buy Signal Bullish 0.00%
Mar 22 Spinning Top Other 0.00%
Mar 22 Down 3 Days in a Row Weakness 0.00%
Mar 22 Down 4 Days in a Row Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Doji - Bullish? Reversal -2.13%
Mar 21 Down 3 Days in a Row Weakness -2.13%
Mar 21 Oversold Stochastic Weakness -2.13%
Mar 20 Oversold Stochastic Weakness -3.00%
Mar 19 NR7 Range Contraction -3.78%

Older signals for DCPH ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Medicine Biopharmaceutical Cancer Alpha Drugs Immune System Cancer Treatments Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Glioblastoma Multiforme Protein Kinase Inhibitor Mastocytosis Treatment For Cancer Systemic Mastocytosis
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.61
52 Week Low 18.55
Average Volume 173,098
200-Day Moving Average 30.3704
50-Day Moving Average 26.7564
20-Day Moving Average 26.6025
10-Day Moving Average 25.399
Average True Range 1.3406
ADX 20.93
+DI 11.2911
-DI 22.6461
Chandelier Exit (Long, 3 ATRs ) 25.9582
Chandelier Exit (Short, 3 ATRs ) 27.6718
Upper Bollinger Band 29.9031
Lower Bollinger Band 23.3019
Percent B (%b) 0.1
BandWidth 24.814209
MACD Line -0.7403
MACD Signal Line -0.3989
MACD Histogram -0.3414
Fundamentals Value
Market Cap 764.28 Million
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -1.49
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.52
Resistance 3 (R3) 25.59 25.15 25.25
Resistance 2 (R2) 25.15 24.75 25.11 25.16
Resistance 1 (R1) 24.54 24.50 24.32 24.47 25.08
Pivot Point 24.10 24.10 23.99 24.06 24.10
Support 1 (S1) 23.49 23.70 23.27 23.42 22.80
Support 2 (S2) 23.05 23.45 23.01 22.72
Support 3 (S3) 22.44 23.05 22.63
Support 4 (S4) 22.37